Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing coronary artery bypass graft (CABG) surgery. It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU.
Investigated for use/treatment in cardiac reperfusion injury, cardiovascular disorders, and coronary artery disease.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.